<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027126</url>
  </required_header>
  <id_info>
    <org_study_id>DEXK-Sil No. 101-18</org_study_id>
    <nct_id>NCT05027126</nct_id>
  </id_info>
  <brief_title>Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen, in Healthy Subjects, Under Fasting Conditions</brief_title>
  <official_title>Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen (Stadium®), Dose 25 mg in Healthy Subjects, of Both Genders, Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioavailability comparison study with a cross-over desing, 2x2, open, prospective and&#xD;
      longitudinal, at a single dose with two treatments, two periods, two sequences with an&#xD;
      elimination (washout) period of 7 days and a number of 36 healthy subjects, of both genders,&#xD;
      under fasting conditions, of reference tablets of Dexketoprofen 25 mg (Stadium®), elaborated&#xD;
      by Grimann, S.A. de C.V., and capsule test drug with Dexketoprofen 25 mg- Vitamin B complex&#xD;
      elaborated by Laboratorios Silanes S.A. de C.V.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed to recruit 36 healthy subjects considering a 2x2 design, where each&#xD;
      subject received both treatments and was its own control. The time was adjusted considering&#xD;
      the half-life of the drugs to be evaluated. Healthy subjects of both genders were selected&#xD;
      since no relevant pharmacokinetic differences related to gender had been reported for the&#xD;
      study drug. The aim of the study was to comparatively evaluate, in the same individuals the&#xD;
      plasma concentrations of Dexketoprofen 25 mg from two pharmaceutical formulations; reference&#xD;
      tablets of Dexketoprofen 25 mg ( Stadium®), elaborated by Grimann, S.A. de C.V., and capsule&#xD;
      test drug with Dexketoprofen 25 mg- Vitamin B complex elaborated by Laboratorios Silanes S.A.&#xD;
      de C.V.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">December 2, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration following the treatment (Cmax)</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing the maximum observed concentration following the treatment (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the curve from time zero to the last measurable concentration (AUC 0-t)</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing the area under the curve from time zero to the last measurable concentration (AUC 0-t)using the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the curve from time zero to infinity calculated (AUC 0-inf)</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing the area under the curve from time zero to infinity (AUC 0-inf), estimated by adding the quotient of the last concentration measured between ke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum measured concentration (Tmax).</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing time of the maximum measured concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate (Ke)</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing the elimination rate (Ke), calculated by log-linear regression of the final phase of elimination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t 1/2)</measure>
    <time_frame>Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 14.00 and 24.00 hours</time_frame>
    <description>Evaluate the fixed dose pharmacokinetics profile of Dexketoprofen-Vitamin B, employing the elimination half-life (t 1/2) by dividing 0.693 / ke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of adverse events</measure>
    <time_frame>2 days</time_frame>
    <description>The percentage of frequency of appearance of each adverse event was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 days</time_frame>
    <description>Any adverse event were classified by severity, treatment and its relationship with the study drug was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A: Dexketoprofen (Stadium®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Drug Pharmaceutical Form: Tablets Dosage: 25 mg Administration way: oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Fixed dose Dexketoprofen-Vitamin B Complex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin, Thiamine,and Pyridoxine. Administration way: oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen 25 MG</intervention_name>
    <description>Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral</description>
    <arm_group_label>Group A: Dexketoprofen (Stadium®)</arm_group_label>
    <other_name>(Stadium®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose Dexketoprofen-Vitamin B Complex</intervention_name>
    <description>Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral</description>
    <arm_group_label>Group B: Fixed dose Dexketoprofen-Vitamin B Complex</arm_group_label>
    <other_name>DEXK / VITB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  That the patient gives informed consent in writing.&#xD;
&#xD;
          -  Be accepted by the COFEPRIS research subjects registry base.&#xD;
&#xD;
          -  Subjects without subordination relationship with the researchers or sponsor. -&#xD;
             Subjects of both genders, aged between 18 and 55, Mexican.&#xD;
&#xD;
          -  No history of hypersensitivity or related drug allergies.&#xD;
&#xD;
          -  Body mass index between 18 and 27 kg / m2&#xD;
&#xD;
          -  Healthy subjects, according to the results of the complete clinical history,&#xD;
             electrocardiogram and the integration of the results of the clinical analyzes, carried&#xD;
             out in certified clinical laboratories, without alterations that, at the discretion of&#xD;
             the Principal Investigator, require medical intervention as a consequence.&#xD;
&#xD;
          -  Subjects with negative results for immunological tests (Anti-HIV (Human&#xD;
             immunodeficiency virus), Anti-hepatitis B and C, VDRL (venereal disease reaction&#xD;
             level)).&#xD;
&#xD;
          -  Subjects with negative results in qualitative tests for the detection of drugs of&#xD;
             abuse: tetrahydro-cannabinoids, cocaine and&#xD;
&#xD;
          -  Research subject that presents alterations in the vital signs recorded during the&#xD;
             selection.amphetamines.&#xD;
&#xD;
          -  Negative (qualitative) pregnancy test in the case of women of childbearing age without&#xD;
             bilateral tubal obstruction or hysterectomy.&#xD;
&#xD;
          -  In the case of women of childbearing age, the subject must sign a letter of commitment&#xD;
             not to pregnancy and have a birth control method, including barrier methods,&#xD;
             non-hormonal intrauterine device or bilateral tubal obstruction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a recent history (3 months) or evidence on physical examination of&#xD;
             gastrointestinal, renal, hepatic, endocrine, respiratory, cardiovascular,&#xD;
             dermatological or hematological disease that could affect the pharmacokinetic study of&#xD;
             the investigational product.&#xD;
&#xD;
          -  Subjects who have been exposed to drugs known as liver enzyme inducers or inhibitors&#xD;
             or who have taken potentially toxic drugs within 30 days prior to the start of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects who have received any medication for 7 days prior to the start of the study.&#xD;
&#xD;
          -  Subjects who have been hospitalized for any problem during the three months prior to&#xD;
             the start of the study.&#xD;
&#xD;
          -  Subjects who have been rejected for their registration in the COFEPRIS research&#xD;
             subject registry database, for having participated in a clinical study within the&#xD;
             three months prior to the start of the study.&#xD;
&#xD;
          -  Subjects who have received investigational drugs within 60 days prior to the study.&#xD;
&#xD;
          -  Subjects allergic to the drug under study or related drugs.&#xD;
&#xD;
          -  Subjects who have ingested alcohol or beverages containing xanthines (coffee, tea,&#xD;
             cocoa, chocolate, cola soft drinks) or who have ingested charcoal-grilled foods or&#xD;
             grapefruit or cranberry juice, at least 10 hours before the start of the study or who&#xD;
             have smoked tobacco within 24 hours prior to the start of the internment period.&#xD;
&#xD;
          -  Subjects who have donated or lost 450 mL or more of blood within the 60 days prior to&#xD;
             the start of the study.&#xD;
&#xD;
          -  Subjects with a history of drug and / or alcohol abuse according to the DSM-IV-TR (&#xD;
             Diagnostic and Statistical Manual of Mental Disorders) Criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Garza Ocaña, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacology and Toxicology of the Faculty of Medicine of the U.A.N.L</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo J Tamez de la O, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacology and Toxicology of the Faculty of Medicine of the U.A.N.L</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratorio Silanes, S.A. de C.V.</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Mexico City</state>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://cima.aemps.es/cima/dochtml/ft/72769/FT_72769.html</url>
    <description>Spanish Agency for Medicines and Health Products (AEMPS). Ministry of Health, Social Policy and Equality. Technical sheet Metamizole ratiopharm 575 mg hard capsules</description>
  </link>
  <link>
    <url>https://www.medicamentosplm.com/Home/productos/stadium_tabletas/160/101/9884/210</url>
    <description>STADIUM. Drugs.</description>
  </link>
  <link>
    <url>http://www.dof.gob.mx/nota_detalle.php?codigo=5314833&amp;fecha=20/09/2013</url>
    <description>Official Mexican standard that establishes the tests and procedures to demonstrate that a drug is interchangeable. Requirements to which the Authorized Third Parties that carry out the interchangeability tests must be subject.</description>
  </link>
  <link>
    <url>http://www.r-project.org/</url>
    <description>R Core Team (2019). R: A language and environment for statistical computing.</description>
  </link>
  <reference>
    <citation>Barbanoj MJ, Gich I, Artigas R, Tost D, Moros C, Antonijoan RM, García ML, Mauleón D. Pharmacokinetics of Dexketoprofen Trometamol in Healthy Volunteers After Single and Repeated Oral Doses. J Clin Pharmacol. 1998 Dec;38(S1):33S-40S. doi: 10.1002/jcph.1998.38.s1.33.</citation>
    <PMID>29023869</PMID>
  </reference>
  <reference>
    <citation>Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet. 2001;40(4):245-62. Review.</citation>
    <PMID>11368291</PMID>
  </reference>
  <reference>
    <citation>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.</citation>
    <PMID>3450848</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexketoprofen</keyword>
  <keyword>Trometamol</keyword>
  <keyword>Cyanocobalamin</keyword>
  <keyword>Thiamine</keyword>
  <keyword>Pyridoxine</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Fixed-dose combination (FDC)</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Dexketoprofen trometamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

